Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
13%
Ph not_applicable
1
13%
Ph phase_1
3
38%
Ph phase_2
3
38%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
1(12.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 31 (12.5%)
N/A1 (12.5%)

Trials by Status

completed563%
recruiting113%
unknown225%

Recent Activity

1 active trials
Showing 5 of 8
completedphase_1

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135
completedphase_1

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

NCT00509353
recruitingphase_2

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT00107289
completedphase_2

Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma

NCT00960739
unknownnot_applicable

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

NCT00526318
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00083135Phase 1

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Completed
NCT00509353Phase 1

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

Completed
NCT00107289Phase 2

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Recruiting
NCT00960739Phase 2

Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma

Completed
NCT00526318Not Applicable

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Unknown
NCT00293319Phase 2

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

Completed
NCT00410631Phase 3

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Unknown
NCT00005978Phase 1

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

Completed

All 8 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
8